Short-Chain Fatty Acids and Stress: What Research Shows

Quick Answer: Do SCFAs Affect the Stress Response?

Human research suggests that short-chain fatty acids may interact with the HPA axis and cortisol response, but the evidence does not support describing SCFAs as a treatment for stress or as substances that simply "reset" cortisol.

In a randomized placebo-controlled trial involving 66 healthy men, one week of colon-delivered acetate, propionate, and butyrate reduced the cortisol response to an acute psychosocial stress task. The intervention did not improve subjective mood, fear learning, or the cortisol awakening response (Dalile et al., 2020, human randomized trial).

The effect also cannot automatically be attributed to butyrate alone. A later randomized trial testing colon-delivered butyrate by itself found no significant change in neuroendocrine or subjective responses to acute stress (Dalile et al., 2024, human randomized trial).

The most accurate conclusion is that SCFAs are plausible microbial signals involved in human stress physiology, while their exact effects depend on the SCFA mixture, biological context, dose, and outcome being measured.

Short-chain fatty acids, or SCFAs, are microbial metabolites produced when gut bacteria ferment certain carbohydrates, particularly fermentable fiber and resistant starch. The three most studied are acetate, propionate, and butyrate.

SCFAs have well-established roles in intestinal physiology and metabolism, but researchers are also studying whether they participate in the body's response to psychological stress. Human evidence is especially interesting because one controlled trial found that a mixture of SCFAs delivered to the colon reduced cortisol reactivity during an acute psychosocial stress task. Other studies, however, show that the relationship is more complicated than a simple more-SCFAs-means-less-stress model.

This article focuses specifically on what human and translational research shows about SCFAs, cortisol reactivity, and the HPA axis, where animal research adds useful mechanistic context, and where current claims go beyond the evidence. For the broader explanation of what SCFAs are, how they are produced, and their roles in the gut barrier and metabolism, see our Short-Chain Fatty Acids guide.

SCFAs in Brief: Acetate, Propionate and Butyrate

Short-chain fatty acids are microbial metabolites produced primarily when bacteria in the colon ferment fermentable carbohydrates. Acetate, propionate, and butyrate account for most of the SCFAs produced in the human colon.

Their established physiological roles extend well beyond stress research. Butyrate is an important fuel for colonocytes, while acetate and propionate enter broader metabolic pathways. SCFAs also participate in immune and receptor-mediated signaling throughout the body (Koh et al., 2016, review).

Those general functions are covered in detail in our Short-Chain Fatty Acids guide. The question here is narrower: whether SCFAs also participate in the human biological response to stress.

How Stress, the Gut Barrier and SCFAs May Interact

Psychological stress can influence gastrointestinal physiology through the HPA axis, autonomic nervous system, immune signaling, and behavioral changes. Laboratory and animal research suggests that these pathways may also affect intestinal barrier function and microbial metabolism.

SCFAs, particularly butyrate, are relevant because they support colonocyte energy metabolism and participate in tight-junction and immune signaling. These mechanisms make SCFAs plausible contributors to barrier resilience.

However, this does not mean that chronic stress universally causes a measurable SCFA deficiency or that increasing SCFAs repairs "stress damage" in humans. Evidence for stress-induced intestinal permeability is considerably stronger in animal and experimental models than in healthy-human research.

The more defensible conclusion is that stress, microbial metabolism, barrier physiology, and immune signaling may interact, while the size and direction of those relationships vary by biological context. For the deeper barrier evidence, see our Gut Barrier Science hub.

What Human Studies Show About SCFAs and Cortisol

The strongest direct human evidence comes from a 2020 triple-blind, randomized, placebo-controlled trial involving 66 healthy men.

Participants received a mixture of acetate, propionate, and butyrate delivered to the colon for one week at doses designed to approximate microbial fermentation of fermentable carbohydrates. Both tested SCFA doses reduced the cortisol response during a standardized psychosocial stress task compared with placebo (Dalile et al., 2020, human randomized trial).

The result is important, but its boundaries matter. SCFA administration did not alter the cortisol awakening response, subjective mood, fear learning, or fear extinction. The study therefore supports a specific effect on acute HPA-axis reactivity rather than a broad claim that SCFAs "calm stress" or improve psychological well-being.

A later randomized trial tested butyrate alone in 71 healthy men. Although the intervention increased circulating butyrate and affected one aspect of fear memory, it did not significantly change subjective or neuroendocrine responses to acute stress (Dalile et al., 2024, human randomized trial).

Taken together, these studies suggest that effects may depend on the combination of SCFAs rather than butyrate alone, and that findings from one experimental intervention should not be generalized to ordinary dietary SCFA production or commercial supplements.

Human Evidence at a Glance

How Do SCFAs Communicate With the HPA Axis?

Researchers are studying several pathways through which SCFAs might influence stress physiology. SCFAs can act on free fatty acid receptors, participate in histone-deacetylase-related signaling, interact with immune and vagal pathways, and influence the gut environment in which other signals are produced. These are plausible routes by which microbial metabolites could reach systems involved in the stress response.

Much of the detailed mechanistic work comes from animal and laboratory studies, so these pathways are best read as biologically plausible rather than as demonstrated human mechanisms. The human trials above show that a colonic SCFA mixture can affect acute cortisol reactivity, but they do not resolve exactly which pathway is responsible or how large the effect is in everyday life.

Can Diet Support SCFA Production?

Dietary fermentable carbohydrates are major substrates for microbial SCFA production. Foods that supply fermentable fiber and resistant starch can therefore support the microbial processes that generate acetate, propionate, and butyrate.

However, eating more fiber does not guarantee a predictable increase in one SCFA or a measurable reduction in cortisol. SCFA production depends on the microbial community, the substrate being fermented, intestinal transit, diet pattern, and other host factors.

A varied diet containing plant foods, fermentable fibers, and resistant starch is a reasonable foundation for general gut health. It should not be presented as a treatment for chronic stress, an HPA-axis disorder, or abnormal cortisol.

What the Research Does Not Show

Current research does not show that low SCFA levels are a common clinical cause of chronic stress, anxiety, poor sleep, cravings, fatigue, or abnormal cortisol.

It also does not establish that increasing SCFAs through food, probiotics, supplements, or other microbiome interventions will reliably lower cortisol or reset the HPA axis.

The 2020 human SCFA-mixture trial provides direct evidence that SCFAs can influence cortisol reactivity under specific experimental conditions. However, the later butyrate-only trial did not reproduce that stress effect, and observational research cannot determine whether microbial SCFA capacity is a cause or consequence of differences in stress physiology.

SCFAs are also being studied in sleep biology, but much of the causal evidence remains preclinical. For the dedicated human sleep evidence and gut-brain mechanisms, see our Gut Microbiome and Sleep and Gut-Brain-Sleep Axis guides.

The most accurate conclusion is that SCFAs are biologically important microbial metabolites with emerging roles in human stress research, not established treatments for stress or cortisol disorders.

The Bottom Line

Short-chain fatty acids are established microbial metabolites with important roles in intestinal and metabolic physiology. Human studies also provide evidence that SCFAs may participate in HPA-axis stress signaling, but the clinical picture is still developing.

One controlled human trial found that a mixture of acetate, propionate, and butyrate reduced cortisol reactivity during acute psychosocial stress. A later study found that butyrate alone did not reproduce that effect, showing why SCFAs should not be treated as interchangeable or described as universal stress-lowering molecules.

The strongest conclusion today is that SCFAs are one possible link between microbial metabolism and human stress physiology. More research is needed before diet, probiotics, SCFA supplements, or microbiome interventions can be recommended as established ways to lower cortisol or treat chronic stress.

Common Questions About SCFAs, Stress and the HPA Axis

1. What are short-chain fatty acids?

Short-chain fatty acids are microbial metabolites, mainly acetate, propionate, and butyrate, produced when gut bacteria ferment certain carbohydrates in the colon. They participate in intestinal, immune, metabolic, and signaling processes.

2. Can SCFAs lower cortisol?

A controlled human trial found that colon-delivered acetate, propionate, and butyrate reduced cortisol reactivity during an acute psychosocial stress task. That does not mean ordinary dietary SCFA production or an SCFA supplement will reliably lower cortisol in everyday life.

3. Does butyrate reduce the stress response?

Not consistently in human research. A later randomized trial testing butyrate alone found no significant change in subjective or neuroendocrine responses to acute stress, even though circulating butyrate increased.

4. Are SCFAs involved in the HPA axis?

Research suggests SCFAs may participate in microbiome-to-host signaling relevant to HPA-axis activity. Human intervention and observational studies support a connection, but the mechanisms and clinical importance remain under investigation.

5. Does chronic stress lower SCFA levels?

Animal studies frequently report stress-related changes in microbial composition and SCFA concentrations, but human evidence is more variable. Chronic stress should not automatically be interpreted as an SCFA deficiency.

6. Can I increase SCFAs through food?

Fermentable fiber and resistant starch provide substrates that gut microbes can convert into SCFAs. However, the amount and balance produced vary according to the microbiome, diet, and host factors. Increasing fiber does not guarantee a specific cortisol or stress effect.

7. Are SCFA supplements proven for stress recovery?

No. Current evidence does not establish oral SCFA supplements as treatments for chronic stress, anxiety, or cortisol disorders. Experimental human studies used specific delivery methods and controlled doses that should not be assumed equivalent to commercial supplements.

8. Are SCFAs connected to sleep?

SCFAs are being studied in sleep and gut-brain research, but much of the detailed causal evidence remains preclinical. Sleep-specific research should be evaluated separately from HPA-axis and stress evidence.

Related Reading

• For what SCFAs are, how they are produced, and their roles in the gut barrier and metabolism, see our Short-Chain Fatty Acids guide.

• For the two-way relationship between stress, cortisol, and the gut microbiome, see Cortisol and the Gut Microbiome.

• For intestinal barrier and permeability evidence, see our Gut Barrier Science hub.

• For strain-specific research on probiotics, mood, and stress, see Psychobiotics and Mental Wellness.

• For the gut-brain mechanisms behind sleep, see our Gut-Brain-Sleep Axis guide.

Scientific References

1. Dalile B, Vervliet B, Bergonzelli G, Verbeke K, Van Oudenhove L.
   Colon-delivered short-chain fatty acids attenuate the cortisol response to psychosocial stress in healthy men: a randomized, placebo-controlled trial 
   Neuropsychopharmacology 2020;45(13):2257-2266
   doi:10.1038/s41386-020-0732-x (Human randomized trial, 66 healthy men)

2. Dalile B, Fuchs A, La Torre D, Vervliet B, Van Oudenhove L, Verbeke K.
   Colonic butyrate administration modulates fear memory but not the acute stress response in men: a randomized, triple-blind, placebo-controlled trial
   Progress in Neuro-Psychopharmacology and Biological Psychiatry 2024;131:110939 
   doi:10.1016/j.pnpbp.2024.110939 (Human randomized trial, 71 healthy men; butyrate alone did not alter the acute stress response)

3. Karner T, Forbes PAG, Berry D, Wagner IC.
   Gut microbial diversity and inferred capacity to produce short-chain fatty acids are associated with acute stress reactivity in healthy adults
   Neurobiology of Stress. 2026;42:100807 
   doi:10.1016/j.ynstr.2026.100807 (Human observational study, 74 adults)

4. Cai W, Stiernborg M, Wolthon A, et al.
   Plasma short-chain fatty acid concentrations in social anxiety disorder and changes after cognitive behavioral therapy
   Translational Psychiatry 2026;16(1):295
   doi:10.1038/s41398-026-04134-y (Longitudinal human study; lifestyle confounders noted by the authors)

5. Koh A, De Vadder F, Kovatcheva-Datchary P, Backhed F.
   From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
   Cell 2016;165(6):1332-1345
   doi:10.1016/j.cell.2016.05.041 (Review of SCFA biology)

Written by Ali Rıza Akın

Microbiome Scientist, Author & Founder of Next-Microbiome

Ali Rıza Akın is a microbiome scientist with nearly 30 years of experience in translational biotechnology, systems biology, and applied microbiome research, spanning discovery, preclinical development, and clinical-stage translation.

His work focuses on how microbial ecosystems interact with human physiology, including:

• Gut barrier function and intestinal permeability

• Mucus-associated microbiota (Akkermansia-related systems)

• Oral–gut microbiome axis

• Short-chain fatty acids (SCFAs) and metabolic signaling

• Circadian rhythm–microbiome interactions
  

Clinical Research Contributions

He has contributed to multiple clinical-stage microbiome programs, supporting bacterial strain discovery, optimization, and formulation design across different therapeutic areas, including:

• Active Ulcerative Colitis (Inflammatory Bowel Disease)

• Hyperoxaluria (Oxalate Metabolism Disorder)

• Microbiome-driven gut health and inflammatory conditions

These studies were part of broader clinical development programs evaluating microbiome-based approaches. His contributions focused on the early-stage scientific and translational pipeline, including strain discovery, functional optimization, and multi-strain formulation design.

Scientific Contributions:

Ali Rıza Akın is the discoverer of Christensenella californii, a bacterial species associated with microbiome diversity and metabolic health.

He is a contributing author to scientific publications and Bacterial Therapy of Cancer (Springer), and the author of Bakterin Kadar Yaşa: İçimizdeki Evren: Mikrobiyotamız.

Approach:

His work emphasizes evidence-based microbiome science, long-term safety, and a systems-based understanding of how microbes influence human health.

Review and Sources

This article is written and reviewed by a microbiome scientist and is based on peer-reviewed human randomized trials, observational research, microbiome physiology studies, and preclinical evidence listed in the Scientific References.

Human intervention findings are distinguished from observational associations and animal mechanisms. Because short-chain fatty acids have broad physiological roles, evidence for gut barrier, metabolic, sleep, or animal outcomes is not treated as proof that SCFAs lower cortisol or treat chronic stress in people. The article is reviewed periodically against current SCFA, microbiome, and stress-physiology research.

Medical Disclaimer

This content is for educational and informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent chronic stress, anxiety, a cortisol disorder, an HPA-axis disorder, or another medical condition. SCFA levels, gut microbiome composition, digestive symptoms, fatigue, sleep changes, or mood symptoms cannot diagnose abnormal cortisol or an HPA-axis condition. Dietary changes, probiotics, and supplements are not substitutes for professional evaluation or evidence-based treatment. Speak with a qualified healthcare professional about persistent or concerning symptoms and before changing a treatment or supplement plan, particularly if you are pregnant, nursing, managing a health condition, or taking medication.

Last reviewed and updated: September 2026